GlassScriptPhysician profile
Jeffrey Chao
NPI 1831139435
$5,631.74
in general payments reported to CMS, 2019-2025
21 companies · $917 in 2025
The $917 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2020: $646 · 2021: $895 · 2022: $940 · 2023: $709 · 2024: $518 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,145.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $842.77 | 2019-2023 | Rexulti |
| Abbvie INC. | $784.16 | 2021-2025 | Vraylar |
| Alkermes, INC. | $766.28 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $517.05 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $512.24 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $429.05 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $367.78 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $232.93 | 2023-2025 | Auvelity |
| Allergan, INC. | $231.60 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $215.43 | 2019-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $182.65 | 2019-2025 | Austedo Xr, Austedo Xr |
| Amgen INC. | $124.88 | 2020 | |
| Eisai INC. | $104.43 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $86.75 | 2025 | Cobenfy |
| Galderma Laboratories, L.P. | $52.70 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $51.23 | 2024-2025 | Spravato |
| Shire North American Group INC | $45.83 | 2019 | |
| Neurocrine Biosciences, INC. | $27.70 | 2025 | |
| Bausch Health US, LLC | $24.03 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.81 | 2023 | Quviviq |
| Indivior INC. | $14.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Chao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.